This edition of our ever-popular Science & Networking focused BioTuesday event is kindly sponsored by RSSL and hosted at the University of Reading on 13 May 2025.  The evening will feature a series of keynotes and company presentations that will provide a broad update on:  'The latest Treatments & Diagnostics for Cardiovascular Disease'.

The evening starts at 18.00 with networking, with presentations beginning at 18.30. Please find the confirmed speaker line-up below: 

17:00 - 17:45  Optional Lab Tour with RSSL (Details below*)

18.00 - 18.30  Guest arrivals and networking

18.30 - 18.35  Welcome by OBN & RSSL 

18.35 - 20.00 Keynotes & Company Presentations 

• Daniel Nicolau​, Associate Principal Scientist from Reading Scientific Services​
• Alexandre Bidaut​, Director of ERBC
• Kate Langton,​ Director of Research at Heart Research UK​
• Chris Jones​, CTO at HaemAnalytica​ 
• Paul Edwards​, Executive Chair at IsomAb​
• Francis White​, CEO, Heart Biotech Nano​
• Ajan Reginald​​, Co-Founder, Executive Officer at Cardiogeni ​

20.00 - 20.30  Audience & Presenter Q&A

20.30 - 21.30  Networking

*RSSL are also offering Lab tours before the event for those that are interested. The meeting location for the lab tour will still be the Meadow Suite and will begin at 5pm. The laboratory we will be touring is a short 2min walk from the venue and the team have some PPE requirements for those that want to attend (no open toe shoes, heels and legs covered). The tour will return to the BioTuesday venue for 5.45pm approx, in time for the evening event. 

Booking Information:

We are pleased to offer complimentary tickets for OBN Members, Active Scientists and Students, with a nominal fee applicable for non-OBN Members.  Click here to book or email events@obn.org.uk for more details.

About RSSL:

End-to-end analytical solutions - Our clients trust us to deliver innovative solutions to real-world problems facing the global life sciences, pharmaceutical, healthcare and personal care sectors.

From our state-of-the-art pharmaceutical lab facilities in Reading, UK, our multi-disciplinary team of >250 scientists works hand in hand with our clients to scope, develop and manufacture innovative drug products that are capable of transforming lives around the world.

We offer a diverse range of biological, microbiological, chemical and physical analytical services as well as pharmaceutical analysis services across all phases of clinical development through to commercial release. We also provide bespoke training and consultancy solutions.

Background information on Cardiovascular Disease:

Cardiovascular diseases, which include heart failure and strokes, are the leading cause of mortality worldwide according to the World Health Organisation (WHO). They account for over 200 000 deaths each year in the UK and blood clot formation, or thrombosis, is the predominant trigger.

Thrombosis risk increases after surgical intervention and with co-morbidities such as cancer and inflammatory diseases. Additionally, as highlighted during the COVID vaccine programme, thrombosis risk in a small subset of people rises with certain vaccines, a concern for vaccine developers. Importantly, anti-coagulants ('blood thinners') can increase the risk of bleeding in some patients, a particular concern in the context of wound healing.

Critical to all normal and abnormal clot-forming processes for haemostasis are platelets. While point-of-care diagnostic tests for platelet function offer speed and ease-of-use, they have typically yielded lower information content limiting patient thrombosis risk-monitoring. However, lab-based blood diagnostics can be time-consuming and harder to standardise.



We will hear from several innovative companies operating in the cardiovascular disease space.